 BURLINGAME, Calif. TUSTIN, Calif.--BUSINESS WIRE--Avid Bioservices, Inc. NASDAQ:CDMO NASDAQ:CDMOP Avid and Humanigen, Inc. NASDAQ:HGEN Humanigen today announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumabTM, Humanigens therapeutic candidate in development for COVID-19. Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor GM-CSF monoclonal antibody designed to prevent and treat an immune h 